| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ESE2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human ELF5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于ELF5抗体的参考文献摘要归纳：
1. **文献名称**：*ELF5 isoform expression is tissue-specific and significantly altered in cancer*
**作者**：Sood et al. (2016)
**摘要**：研究通过Western Blot和免疫组化分析多种癌细胞系，发现ELF5抗体能特异性识别不同亚型，揭示其在乳腺癌中表达显著下调并与患者预后相关。
2. **文献名称**：*Epigenetic regulation of Elf5 in breast cancer*
**作者**：Chakrabarti et al. (2012)
**摘要**：利用ELF5抗体进行染色质免疫沉淀(ChIP-seq)，证实DNA甲基化抑制ELF5转录，导致乳腺癌细胞上皮-间质转化(EMT)增强，促进转移。
3. **文献名称**：*ELF5 is a key regulator of embryonic trophoblast stem cells*
**作者**：Donnison et al. (2015)
**摘要**：通过免疫荧光技术结合ELF5抗体，发现该蛋白在小鼠胚胎滋养层干细胞中高表达，对维持干细胞多能性和胎盘发育至关重要。
注：若需具体文献编号或补充内容，可提供更详细关键词进一步筛选。
The ELF5 antibody is a crucial tool in studying the E74-like factor 5 (ELF5), a member of the Ets transcription factor family. ELF5 plays pivotal roles in embryonic development, tissue differentiation, and cancer biology. It is particularly implicated in mammary gland development, where it regulates luminal epithelial cell differentiation and lactation. In cancer research, ELF5 exhibits dual roles depending on context: it acts as a tumor suppressor in estrogen receptor-positive (ER+) breast cancers by repressing EMT (epithelial-mesenchymal transition) and metastasis, yet promotes aggressiveness in triple-negative breast cancer (TNBC). Dysregulation of ELF5 is also linked to prostate, ovarian, and endometrial cancers.
ELF5 antibodies enable detection and quantification of ELF5 protein expression in tissues or cell lines via techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence. These antibodies help investigate ELF5's transcriptional regulatory mechanisms, its interaction with co-factors (e.g., DNA, other proteins), and its clinical relevance as a biomarker for cancer prognosis or therapy response. Commercial ELF5 antibodies are typically raised against specific epitopes (e.g., N-terminal regions) and validated for specificity using knockout controls. Researchers prioritize antibodies with high affinity and minimal cross-reactivity to related Ets proteins. Ongoing studies leverage ELF5 antibodies to explore its therapeutic potential in targeting cancer stem cells or reversing treatment resistance.
×
